Skip to main content
Signal8

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Form 10-Q — Nov 16, 2026

$BCLIForm 10-QFiled Nov 16, 2026, 4:34 PM ET0001104659-26-128417Original filing

BrainStorm Cell Therapeutics filed its Q3 2026 10-Q with substantial doubt about its ability to continue as a going concern, reporting just $348,000 in cash, cash equivalents and restricted cash against a $12.7 million working capital deficit. The company's net loss for the nine months ended September 30, 2026 was $7.7 million, and it has never generated revenue. It was delisted from Nasdaq in 2025 and now trades on OTCQB, and management disclosed a material weakness in internal controls over short-term loan transactions that has not yet been remediated.

Key figures

Total Assets
840000
Cash Position
163000
Shares Outstanding
14259377
Restricted cash
185000
Rnd nine months
2248000
Accounts payable
7473000
Short term loans
1875000
Ichilov claim nis
2117950
Net cash financing
2991000
Accumulated deficit
245000000
Cash restricted total
348000
Working capital deficit
12719000
Total current liabilities
13172000

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Form 10-Q — Nov 16, 2026: AI Analysis | Signal8